Acadia Pharmaceuticals (ACAD) Total Non-Current Liabilities (2010 - 2026)

Acadia Pharmaceuticals' Total Non-Current Liabilities history runs 16 years deep, the most recent figure standing at $344.5 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities fell 0.76% year-over-year to $344.5 million; the TTM figure through Mar 2026 stood at $344.5 million (down 0.76% YoY), while the FY2025 annual figure was $317.7 million, down 27.29% from the prior year.
• Total Non-Current Liabilities was $344.5 million for Q1 2026 at Acadia Pharmaceuticals, up from $317.7 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $436.9 million in Q4 2024 to a low of $170.3 million in Q3 2022.
• Historically, Total Non-Current Liabilities has averaged $302.3 million across 5 years, with a median of $317.7 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities soared 69.38% in 2023, then decreased 27.29% in 2025.
• A 5-year view of Total Non-Current Liabilities shows it stood at $178.3 million in 2022, then jumped by 69.38% to $302.1 million in 2023, then soared by 44.65% to $436.9 million in 2024, then fell by 27.29% to $317.7 million in 2025, then rose by 8.46% to $344.5 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $344.5 million (Q1 2026), $317.7 million (Q4 2025), and $399.6 million (Q3 2025), per Business Quant data.